Literature DB >> 17117295

Redefining osteoporosis treatment: Who to treat and how long to treat.

E Michael Lewiecki1, Stuart L Silverman.   

Abstract

Osteoporosis is a common disease that is associated with increased risk of fractures and serious clinical consequences. Bone mineral density (BMD) testing is used to diagnose osteoporosis, estimate the risk of fracture, and monitor changes in BMD over time. Combining clinical risk factors for fracture with BMD is a better predictor of fracture risk than BMD or clinical risk factors alone. Methodologies are being developed to use BMD and validated risk factors to estimate the 10-year probability of fracture, and then combine fracture probability with country-specific economic assumptions to determine cost-effective intervention thresholds. The decision to treat is based on factors that also include availability of therapy, patient preferences, and co-morbidities. All patients benefit from nonpharmacological lifestyle treatments such a weight-bearing exercise, adequate intake of calcium and vitamin D, fall prevention, avoidance of cigarette smoking and bone-toxic drugs, and moderation of alcohol intake. Patients at high risk for fracture should be considered for pharmacological therapy, which can reduce fracture risk by about 50%.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117295     DOI: 10.1590/s0004-27302006000400015

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  7 in total

1.  The effects of loaded versus unloaded activities on foot volumetrics in older healthy adults.

Authors:  J Wesley McWhorter
Journal:  N Am J Sports Phys Ther       Date:  2008-02

Review 2.  Individualizing osteoporosis therapy.

Authors:  S Silverman; C Christiansen
Journal:  Osteoporos Int       Date:  2012-01-05       Impact factor: 4.507

Review 3.  What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

Authors:  P D Miller; R J Derman
Journal:  Osteoporos Int       Date:  2010-03-23       Impact factor: 4.507

4.  Identification of candidate genes in osteoporosis by integrated microarray analysis.

Authors:  J J Li; B Q Wang; Q Fei; Y Yang; D Li
Journal:  Bone Joint Res       Date:  2016-12       Impact factor: 5.853

5.  Screening of osteoprotegerin-related feature genes in osteoporosis and functional analysis with DNA microarray.

Authors:  Xiaoming Wu; Shuzhang Guo; Guanghao Shen; Xing Ma; Chi Tang; Kangning Xie; Juan Liu; Wei Guo; Yili Yan; Erping Luo
Journal:  Eur J Med Res       Date:  2013-06-03       Impact factor: 2.175

6.  Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab.

Authors:  S Scheiner; P Pivonka; D W Smith; C R Dunstan; C Hellmich
Journal:  Int J Numer Method Biomed Eng       Date:  2013-08-30       Impact factor: 2.747

7.  The Evaluation of Bone Mineral Density based on Age and Anthropometric Parameters in Southeast Chinese Adults: A Cross-Sectional Study.

Authors:  Rongrong Xuan; Yang Song; Julien S Baker; Yaodong Gu
Journal:  Med Sci Monit       Date:  2020-08-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.